Cannabis and cannabinoids for the treatment of people with chronic noncancer pain conditions: a systematic review and meta-analysis of controlled and observational studies.

Published on Oct 1, 2018in Pain6.029
· DOI :10.1097/j.pain.0000000000001293
Emily Stockings14
Estimated H-index: 14
Gabrielle Campbell17
Estimated H-index: 17
+ 7 AuthorsLouisa Degenhardt91
Estimated H-index: 91
This review examines evidence for the effectiveness of cannabinoids in chronic noncancer pain (CNCP) and addresses gaps in the literature by: considering differences in outcomes based on cannabinoid type and specific CNCP condition; including all study designs; and following IMMPACT guidelines. MEDLINE, Embase, PsycINFO, CENTRAL, and clinicaltrials. gov were searched in July 2017. Analyses were conducted using Revman 5.3 and Stata 15.0. A total of 91 publications containing 104 studies were eligible (n = 9958 participants), including 47 randomised controlled trials (RCTs) and 57 observational studies. Forty-eight studies examined neuropathic pain, 7 studies examined fibromyalgia, 1 rheumatoid arthritis, and 48 other CNCP (13 multiple sclerosis-related pain, 6 visceral pain, and 29 samples with mixed or undefined CNCP). Across RCTs, pooled event rates (PERs) for 30% reduction in pain were 29.0% (cannabinoids) vs 25.9% (placebo); significant effect for cannabinoids was found; number needed to treat to benefit was 24 (95% confidence interval [CI] 15-61); for 50% reduction in pain, PERs were 18.2% vs 14.4%; no significant difference was observed. Pooled change in pain intensity (standardised mean difference:-0.14, 95% CI-0.20 to -0.08) was equivalent to a 3mm reduction on a 100 mm visual analogue scale greater than placebo groups. In RCTs, PERs for all-cause adverse events were 81.2% vs 66.2%; number needed to treat to harm: 6 (95% CI 5-8). There were no significant impacts on physical or emotional functioning, and low-quality evidence of improved sleep and patient global impression of change. Evidence for effectiveness of cannabinoids in CNCP is limited. Effects suggest that number needed to treat to benefit is high, and number needed to treat to harm is low, with limited impact on other domains. It seems unlikely that cannabinoids are highly effective medicines for CNCP.
  • References (0)
  • Citations (46)
📖 Papers frequently viewed together
13 Authors (Penny Whiting, ..., JosKleijnen)
526 Citations
51 Citations
71 Citations
78% of Scinapse members use related papers. After signing in, all features are FREE.
Cited By46
#1Namkee G. Choi (University of Texas at Austin)H-Index: 29
#2Diana M. DiNitto (University of Texas at Austin)H-Index: 15
Last. Bryan Y. Choi (Brown University)H-Index: 8
view all 3 authors...
Objectives: To examine rates and correlates of dual cannabis and prescription pain reliever (PPNR) use and misuse among U.S. individuals aged 50+ who reported past-year cannabis use.Methods: Using the 2015-2018 National Survey of Drug Use and Health, we examined cannabis nonuse/use and PPNR nonuse/use/misuse among all 35,229 respondents, and then focused on 2,632 past-year cannabis users to examine the risk of PPNR use but no misuse and the risk of PPNR misuse, compared to PPNR nonuse.Results: M...
#1Cari Levy (CU: University of Colorado Boulder)H-Index: 15
view all 3 authors...
The purpose of this article is to present evidence on the efficacy and safety of medical cannabis as a therapy for symptom management in palliative care. This article provides an overview of the evidence on the risks and benefits of using medical cannabis for the indications of chronic pain, cancer-related pain, cancer cachexia, dementia, and Alzheimer's disease. Currently, there is insufficient evidence to determine the effectiveness and safety of cannabinoids for most reviewed indications, wit...
#1Adam Stasiulewicz (University of Warsaw)
#2Katarzyna Znajdek (University of Warsaw)
Last. And Joanna I Sulkowska (University of Warsaw)
view all 5 authors...
The endocannabinoid system (ECS) is one of the most crucial systems in the human organism, exhibiting multi-purpose regulatory character. It is engaged in a vast array of physiological processes, including nociception, mood regulation, cognitive functions, neurogenesis and neuroprotection, appetite, lipid metabolism, as well as cell growth and proliferation. Thus, ECS proteins, including cannabinoid receptors and their endogenous ligands’ synthesizing and degrading enzymes, are promising therape...
#1Shanna Babalonis (UK: University of Kentucky)H-Index: 8
#2Sharon L. WalshH-Index: 21
Abstract The endogenous opioid and cannabinoid receptor systems are widely distributed and co-localized throughout central and peripheral nervous system regions. A large body of preclinical evidence suggests that there are functional interactions between these two systems that may be leveraged to address various health conditions. Numerous animal studies have shown that cannabinoid agonists (e.g., delta-9-tetrahydrocannabinol [Δ9-THC]) enhance the analgesic effects of µ-opioid analgesics as evid...
#1Marcello Mario Mascia (University of Cagliari)H-Index: 5
#2Daniele Carmagnini (University of Cagliari)H-Index: 1
Last. Giovanni Defazio (University of Cagliari)H-Index: 33
view all 3 authors...
Dystonia is a movement disorder characterized by sustained or intermittent muscle contractions causing abnormal movements and postures. Besides motor manifestations, patients with dystonia also display non-motor signs and symptoms including psychiatric and sensory disturbances. Symptomatic treatment of motor signs in dystonia largely relies on intramuscular botulinum toxin injections and, in selected cases, on deep brain stimulation. Oral medications and physical therapy offer a few benefits onl...
1 CitationsSource
#1Stanley Wong (HKU: University of Hong Kong)H-Index: 8
#2Wing Shing Chan (HKU: University of Hong Kong)
Last. Chi Wai Cheung (HKU: University of Hong Kong)H-Index: 18
view all 3 authors...
There is growing interest in using cannabinoids for chronic pain. We performed a systematic review and meta-analysis of randomized controlled trials to evaluate the analgesic efficacy and adverse effects of cannabinoids for chronic non-cancer pain. PubMed, EMBASE, Web of Science, Cochrane CENTRAL and were searched up to December 2018. Information on the type, dosage, route of administration, pain conditions, pain scores, and adverse events were extracted for qualitative analys...
#1Jennifer H. Martin (University of Newcastle)H-Index: 31
#2Wayne Hall (UQ: University of Queensland)H-Index: 89
Last. José Alexandre de Souza Crippa (USP: University of São Paulo)H-Index: 52
view all 5 authors...
1 CitationsSource
#2Kristin SalottoloH-Index: 13
Last. David Bar-OrH-Index: 28
view all 6 authors...
Background To determine whether adjunctive dronabinol, a licensed form of delta-9-tetrahydrocannabinol, reduces opioid consumption when used off-label for managing acute pain following traumatic injury. Methods This matched cohort study included patients who were admitted with a traumatic injury between 1 March 2017 and 30 October 2017. The hospital pharmacy database was used to identify patients who received dronabinol (cases), and they were matched 1:1 to patients who did not receive dronabino...
1 CitationsSource
#1Robert P. RunnerH-Index: 5
#2Andrew N. LuuH-Index: 2
Last. Robert S. GorabH-Index: 7
view all 7 authors...
abstract Introduction Given the opioid crisis in America, patients are trying alternative medications including Tetrahydrocannabinol (THC) and other Cannabidiol (CBD) containing products in the perioperative period, especially in states where these products are legal. This study sought to analyze usage rates of CBD/THC products in the perioperative period for primary unilateral total hip and knee arthroplasty (THA/TKA) patients and identify a possible association with postoperative opioid use. M...
#1Yi Luo (University of Texas MD Anderson Cancer Center)H-Index: 2
#2Jixiang Zhang (University of Texas MD Anderson Cancer Center)H-Index: 3
Last. Hui Lin Pan (University of Texas MD Anderson Cancer Center)H-Index: 48
view all 7 authors...
Type 1 cannabinoid receptors (CB1Rs) are expressed in the dorsal root ganglion (DRG) and contribute to the analgesic effect of cannabinoids. However, the epigenetic mechanism regulating the expression of CB1Rs in neuropathic pain is unknown. G9a (encoded by the Ehmt2 gene), a histone 3 at lysine 9 methyltransferase, is a key chromatin regulator responsible for gene silencing. In this study, we determined G9a's role in regulating CB1R expression in the DRG and in CB1R-mediated analgesic effects i...